Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun;53(11):1236-1240.
doi: 10.1111/apt.16349.

Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study

Christopher A Lamb  1 , Shaji Sebastian  2 , Alexandra J Kent  3 , Jonathan P Segal  3 , Haidee A Gonzalez  2 , Matthew J Brookes  4 , Shameer J Mehta  3 , Sreedhar Subramanian  5 , Neeraj Bhala  6 , Lucy C Hicks  3 , Thomas E Conley  5 , Kamal V Patel  3 , Gareth J Walker  7 , Nicholas A Kennedy  8 ; PREPARE-IBD Study Group
Affiliations
Comment

Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study

Christopher A Lamb et al. Aliment Pharmacol Ther. 2021 Jun.

Abstract

LINKED CONTENT

This article is linked to Taxonera et al paper. To view this article, visit https://doi.org/10.1111/apt.15804

PubMed Disclaimer

Comment on

References

    1. Taxonera C, Sagastagoitia I, Alba C, Manas N, Olivares D, Rey E. 2019 novel coronavirus disease (COVID‐19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2020;52:276‐283. - PMC - PubMed
    1. Kennedy NA, Jones G‐R, Lamb CA, et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID‐19 pandemic. Gut. 2020;69:984‐990. - PMC - PubMed
    1. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow‐up in the TREAT registry. Am J Gastroenterol. 2012;107:1409‐1422. - PMC - PubMed
    1. Wisniewski A, Kirchgesner J, Seksik P, et al. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. United European Gastroenterol J. 2020;8:303‐313. - PMC - PubMed
    1. Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray‐Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155:337‐346.e10. - PubMed

LinkOut - more resources